Ulotaront
SEP-363856 · SEP-856
Last updated
At a glance
Overview
Why Ulotaront Is on the Radar#
Ulotaront (SEP-363856) is the first TAAR1 / 5-HT1A agonist to clear Phase 2 in schizophrenia, and the reason the nootropic-curious corner of the community is paying attention has nothing to do with psychosis. The molecule modulates dopamine presynaptically — dialing the system down through trace amine receptor activation rather than blocking D2 postsynaptically — and layers 5-HT1A agonism on top for an anxiolytic, anti-anhedonic tone.
"Ulotaront (SEP-363856), a novel trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) receptor agonist, was not associated with dopamine D2, 5-HT2A, muscarinic, or histaminergic receptor binding at clinically relevant concentrations." — Koblan et al., NEJM (2020)
The practical appeal is the safety signature: across 26 weeks of open-label data, mean weight change was –0.3 kg, EPS rates tracked placebo, prolactin was untouched, and metabolic markers stayed flat — a profile no D2 antagonist comes close to. Headline effects in the published program are reduced anxiety, motivational lift, and REM suppression with increased REM latency as a consistent PD marker of TAAR1 engagement. Functional dose window from the trials is 25–75 mg once daily, orally, with a ~7-hour half-life and no food effect on exposure.
Honesty up front: ulotaront missed its primary endpoint in the Phase 3 DIAMOND schizophrenia readouts, it is not a gray-market compound with established vendor channels, and there is no validated bodybuilding or looksmaxxing use case — the receptor profile is interesting, but human data outside the schizophrenia / MDD / GAD programs does not exist. The sections below cover the documented PK, the 25–100 mg dose ladder from the clinical program, the REM-sleep and cardiac signals worth knowing about, the mechanistic rationale for stacking (and what not to combine it with), and an honest read on where ulotaront actually sits in the current research-chem landscape.
How Ulotaront works
Ulotaront is the first compound in its class — a trace amine-associated receptor 1 (TAAR1) full agonist with secondary 5-HT1A receptor agonist activity. What makes it pharmacologically interesting is what it doesn't touch: no D2, no 5-HT2A, no muscarinic, no histaminergic binding at clinically relevant concentrations. The entire mechanism is built around modulating dopamine tone without postsynaptic dopamine blockade — a fundamentally different approach from every classical or atypical antipsychotic on the market.
"Ulotaront (SEP-363856), a novel trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT1A) receptor agonist, was not associated with dopamine D2, 5-HT2A, muscarinic, or histaminergic receptor binding at clinically relevant concentrations." — Koblan KS, Kent J, Hopkins SC, et al., New England Journal of Medicine, 2020
TAAR1 Agonism: Presynaptic Dopamine Restraint#
TAAR1 is a Gαs-coupled receptor expressed on midbrain dopamine neurons in the ventral tegmental area and substantia nigra. Activation drives the cAMP–PKA–CREB cascade and engages DARPP-32 signaling, with a parallel β-arrestin2-dependent Akt/GSK-3β arm via TAAR1–D2 heterodimerization. The functional output is reduced firing of midbrain dopamine neurons and attenuation of stimulant-induced presynaptic dopamine release.
"TAAR1 agonism modulates dopaminergic, glutamatergic, and serotonergic neurotransmission by regulating presynaptic dopamine neuron firing and neurotransmitter release, differentiating the mechanism from traditional D2 antagonists." — Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD., International Journal of Molecular Sciences, 2021
The practical translation: dopamine signaling is dialed down through presynaptic restraint rather than postsynaptic blockade. That's why the trial dataset shows no extrapyramidal symptoms, no prolactin elevation, and no meaningful weight or metabolic disturbance — none of the receptor systems responsible for those side effects are engaged.
5-HT1A Agonism: The Anxiolytic and Antidepressant Axis#
The secondary mechanism is 5-HT1A receptor agonism — the same axis exploited by buspirone, tandospirone, and (partially) vilazodone and vortioxetine. Presynaptic 5-HT1A autoreceptor activation on dorsal raphe neurons reduces serotonergic firing acutely, while chronic stimulation drives autoreceptor desensitization and a net increase in forebrain serotonergic tone. Postsynaptic 5-HT1A activation in cortical and limbic regions contributes to anxiolytic and antidepressant-like effects in preclinical models, and is the mechanistic basis for the adjunctive MDD and GAD development programs.
This axis is also why combining with MAOIs is contraindicated on class logic, and why the MDD program was specifically structured as adjunctive on SSRI/SNRI backgrounds — the serotonergic load is non-trivial and warrants a designed background.
Glutamatergic and Cortical Modulation#
TAAR1 activation indirectly modulates cortical glutamate transmission, attenuating NMDA-receptor hypofunction signatures in preclinical models — including reversal of PCP- and ketamine-induced hyperactivity and prefrontal dysfunction. The mechanism appears to involve normalization of presynaptic dopamine drive to cortical and striatal circuits rather than direct glutamate receptor binding. For the cognition-curious reader, this is the axis most plausibly tied to negative-symptom and anhedonia improvement in the schizophrenia and MDD datasets — the symptom domain that responds poorly to every D2-targeting drug.
REM Sleep Suppression and Sleep Architecture#
A consistent, mechanistically-linked finding across the TAAR1 class is REM sleep suppression with increased REM latency. Ulotaront produces this signature reliably.
"REM sleep suppression and increased REM latency—hallmarks of TAAR1 activation—were observed consistently with ulotaront administration." — Kuvarzin SR, Sukhanov I, Onokhin K, Zakharov K, Gainetdinov RR., Biomedicines, 2023
This is mechanism, not side effect — but it has practical implications. Morning administration is the documented schedule precisely because late-day dosing compounds REM suppression at a time of day when it cannot be offset. Chronic REM suppression has its own downsides for memory consolidation and emotional processing, so this is a feature to track rather than ignore.
Metabolic and Endocrine Cleanliness#
Because none of the off-target receptor systems are engaged, the metabolic profile across 6 months of administration is effectively flat:
"Mean changes in weight and metabolic parameters were minimal over 26 weeks, with a mean weight change of –0.3 kg and low rates of extrapyramidal symptoms reported." — Correll CU, Koblan KS, Hopkins SC, et al., NPJ Schizophrenia, 2021
For an audience already managing body composition, lipids, and insulin sensitivity around a cycle, this matters: ulotaront does not move weight, lipids, HbA1c, or prolactin in any clinically meaningful way. It is also not androgen- or HPG-active — there is no interaction with an AAS cycle characterized in the literature, and no PCT implications. The mechanism lives entirely in the monoaminergic and trace-aminergic compartments.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 25–50 mg | Once daily | Documented entry-level range |
| Mid | 50–75 mg | Once daily | Most commonly studied range |
| High | 75–100 mg | Once daily | Morning administration is the documented schedule. Food does not affect Cmax or AUC but delays Tmax by ~1.5 h. Late-day dosing compounds REM-suppression effects. |
Cycle length & outcomes
Documented cycle
4–26 weeks
Plateau after
26 wks
Cycle Length & Onset Timing#
Ulotaront is a once-daily oral agent with documented protocols running 4 to 26 weeks. There is no loading phase, no titration requirement in the published trials, and no taper protocol — the molecule was started at target dose in both Phase 2 and Phase 3, and the 26-week open-label extension data showed continued symptom improvement without dose escalation (Correll et al., 2021).
Onset timing breaks down by endpoint:
- Anxiolytic / 5-HT1A-mediated effects: emerge within the first 1–2 weeks, consistent with the buspirone-class onset profile.
- TAAR1-mediated dopaminergic modulation: PANSS separation from placebo became significant by week 2 and continued widening through week 4 in the pivotal Phase 2 trial (Koblan et al., 2020).
- REM sleep architecture changes: appear within the first few nights of administration — REM latency increases and REM duration decreases acutely (Kuvarzin et al., 2023).
- Metabolic profile: stays flat across the full 26-week window — mean weight change of –0.3 kg with no clinically meaningful lipid or HbA1c drift.
Dose Ladder by Goal#
The dose ladder below reflects the range that has actual evidence behind it from the Phase 2, OLE, and DIAMOND programs. There is no off-label community ladder for ulotaront — it has not penetrated the gray market — so anything outside this window is uncharted.
| Goal | Cycle Length | Daily Dose |
|---|---|---|
| Anxiolytic / 5-HT1A-driven calm | 4–8 weeks | 25–50 mg |
| Anhedonia / motivational adjunct (on SSRI/SNRI background) | 6–12 weeks | 25–75 mg |
| Full TAAR1 engagement (schizophrenia-program dose) | 4–6 weeks acute, up to 26 weeks continuation | 50–75 mg |
| Upper documented range (DIAMOND 2) | 6 weeks | 75–100 mg |
"Ulotaront exhibited dose-proportional increases in exposure across the 10- to 100-mg dose range, with a median effective half-life of approximately 7 hours following oral administration." — Galluppi et al., 2021
The dose-response curve is a plateau above ~75 mg — DIAMOND 2 pushed to 100 mg and did not produce meaningfully better outcomes than the 75 mg arm, just a slightly higher rate of somnolence and GI side effects. There is no benefit to chasing the top of the range.
Administration Schedule#
- Timing: morning, once daily. Late-day administration compounds REM-suppression effects and disrupts sleep architecture beyond the baseline TAAR1 signature.
- Food: irrelevant to total exposure. Fed administration delays Tmax by ~1.5 h but leaves Cmax and AUC unchanged (Tsai et al., 2023) — fasted or fed is a preference call, not a pharmacokinetic one.
- Formulation: 25 mg tablet and 25 mg capsule are bioequivalent within 80–125%.
- Accumulation: steady-state ratio of 1.10 means the dose at day 1 is functionally the dose at day 30. No "building up" to expect.
Loading & Tapering#
Neither is required. The Phase 2 and Phase 3 programs started subjects at target dose without titration and discontinued without tapering. The TAAR1/5-HT1A receptor profile does not produce the receptor downregulation that creates withdrawal syndromes with D2 antagonists or SSRIs — there is no documented discontinuation syndrome.
That said, abrupt cessation after multi-month administration has not been formally characterized in healthy subjects. A conservative 1–2 week dose halving (e.g. 75 mg → 50 mg → 25 mg → off) is reasonable extrapolation for anyone running the upper end of the range for the full 26-week window.
Bloodwork & Monitoring Cadence#
Ulotaront has a remarkably clean metabolic panel — no prolactin elevation, no weight gain, no lipid drift, no HbA1c change at 26 weeks (Correll et al., 2021). Monitoring is light:
| Marker | Baseline | On-Cycle | Rationale |
|---|---|---|---|
| ECG (QTc) | Yes | Week 4, then quarterly | One sudden cardiac death in the Phase 2 active arm; causality unestablished but signal is in the record |
| CMP + lipid panel | Yes | Week 8, then every 12 weeks | Baseline characterization; ulotaront itself drives no meaningful shift |
| CBC | Yes | Every 12 weeks | General safety baseline |
| Sleep log / REM tracking | Yes (Oura/WHOOP/8Sleep) | Continuous | REM suppression is mechanistic and consistent |
| Prolactin / HbA1c | Optional | Not required | No signal in trial data |
"Mean changes in weight and metabolic parameters were minimal over 26 weeks, with a mean weight change of –0.3 kg and low rates of extrapyramidal symptoms reported." — Correll et al., 2021
The single most useful piece of monitoring outside standard panels is REM sleep tracking. Chronic REM suppression has downstream consequences for memory consolidation and emotional processing that the trial endpoints were not designed to capture, and any cycle running past 8–12 weeks benefits from objective sleep architecture data.
Cycle Strategy#
Short cycles (4–8 weeks) at 25–50 mg are the most defensible use case for the nootropic-curious audience — the 5-HT1A axis carries the anxiolytic load, TAAR1 modulation tunes dopaminergic reactivity downward, and the metabolic and endocrine footprint is functionally absent. Longer cycles (12–26 weeks) have safety data behind them but are uncharted outside the clinical indications, and the REM-suppression signal becomes more relevant the longer the cycle runs.
No PCT. No HPG axis involvement. No interaction with AAS, SARMs, or peptide stacks has been characterized, so layering ulotaront onto an active anabolic cycle is an unstudied combination — the receptor profile predicts no pharmacological conflict, but predicts is not data.
Risks & mistakes
Common (most users)#
- Somnolence — the most frequently reported effect in the Phase 2/3 program. Morning administration is the documented schedule; late-day dosing compounds the effect and stacks with REM suppression. If daytime drowsiness persists past week 1, the protocol calls for dropping from 75 mg to 50 mg.
- Headache — typically mild, early-treatment. Hydration and a stable caffeine intake during initiation cover most cases.
- Nausea / dyspepsia — usually transient. Co-administration with food does not alter Cmax or AUC but delays Tmax by ~1.5 h, which softens the GI profile without sacrificing exposure (Tsai et al., 2023).
- Early-treatment agitation — reported in the acute schizophrenia trials, generally resolving within the first 1–2 weeks. Not a reason to dose-escalate.
"Ulotaront exhibited dose-proportional increases in exposure across the 10- to 100-mg dose range, with a median effective half-life of approximately 7 hours following oral administration." — Galluppi et al., 2021
Uncommon (dose-dependent or individual)#
- REM sleep suppression and increased REM latency — mechanistic and consistent across the TAAR1 class, not an idiosyncratic reaction. Subclinical at standard doses but worth tracking with a sleep log; chronic REM debt has its own downstream cost. Back off toward the 25–50 mg range if sleep architecture feels degraded.
- Mild metabolic shift — Phase 2 open-label extension at 26 weeks showed a mean weight change of –0.3 kg, median cholesterol –2 mg/dL, triglycerides –5 mg/dL. Essentially flat, but individuals on the tails of the distribution exist. Baseline + 12-week lipid panel is sensible.
- Serotonergic load when stacked — the MDD program ran ulotaront adjunctively on SSRI/SNRI backgrounds without clinically meaningful serotonergic events, but the 5-HT1A axis still adds tone. Stacking with other strong serotonergic agents warrants conservative dosing and symptom monitoring (tremor, hyperreflexia, autonomic instability).
- Orthostatic / autonomic effects — uncommon and dose-related at the upper end of the 75–100 mg range. A baseline blood pressure check covers it.
"Mean changes in weight and metabolic parameters were minimal over 26 weeks, with a mean weight change of –0.3 kg and low rates of extrapyramidal symptoms reported." — Correll et al., 2021
Rare but serious#
- Sudden cardiac event — one sudden cardiac death occurred in the ulotaront arm of the pivotal Phase 2 trial. Causality was not established and the broader dataset showed no QTc signal, but the event is in the public record (Koblan et al., 2020). A baseline ECG with QTc measurement is the appropriate response, particularly in anyone with a family history of arrhythmia or prior abnormal conduction. Syncope, palpitations, or unexplained chest pain are stop signals.
- Serotonin syndrome — theoretical with combined serotonergic agents, particularly MAOIs. Hyperthermia, clonus, agitation, and autonomic instability require immediate discontinuation.
- Hypersensitivity reactions — not characterized in the clinical literature beyond background rates, but a low-probability concern for any novel small molecule.
Hard contraindications#
- MAOI use — mechanistically incompatible with a 5-HT1A agonist carrying monoaminergic activity. Do not combine.
- Pregnancy and lactation — no human data. The line is not crossed.
- Known QTc prolongation or congenital long QT — given the Phase 2 sudden-death signal, a documented QTc abnormality is a hard stop until the question is resolved with a cardiologist.
- Primary psychotic disorder requiring D2 blockade — ulotaront has no D2 occupancy. It is not a substitute for an established antipsychotic in patients whose symptom control depends on D2 antagonism. The DIAMOND 1/2 failures underline this; ulotaront is not a rescue agent.
- Unverified source material — ulotaront does not have a vetted gray-market supply chain. Anything not third-party HPLC-confirmed should be assumed mislabeled.
Sex-specific and ancillary considerations#
Population PK identified body weight as the only meaningful covariate; sex did not produce clinically relevant exposure differences, and no dose adjustment by sex is supported by the data (Galluppi et al., 2021). Pregnancy and lactation remain hard contraindications on a no-data basis. Ulotaront is not androgen- or HPG-active — there is no prolactin elevation, no gonadotropin effect, and no PCT requirement. It does not interact with an AAS cycle in any characterized way and carries no ancillary requirement of its own; the only mechanistic co-medication rule is the MAOI contraindication above.
FAQ — Ulotaront
Research & citations
5 studies cited on this page.
Conclusion
Ulotaront stands out as the first bona fide TAAR1/5-HT1A agonist with robust trial data and a uniquely clean side effect profile in high-dose, long-duration protocols.
Key takeaways:
- Documented dose range: 25–75 mg once daily, oral administration; 50 mg is the standard starting dose
- Cycle length in trials: 4–26 weeks, with no titration needed and minimal accumulation
- Mechanism: presynaptic dopaminergic modulation via TAAR1, anxiolytic/antidepressant signature from 5-HT1A agonism — zero D2 blockade or metabolic drag
- REM sleep suppression is mechanistically consistent; late-day dosing accentuates this effect
- Side effects are typically limited to mild somnolence or GI symptoms; no weight gain or extrapyramidal risk observed (Correll et al., NPJ Schizophrenia 2021)
- Stacking with SSRIs/SNRIs is trial-backed for MDD and GAD; MAOI coadministration is contraindicated
For anyone exploring TAAR1/5-HT1A agonism in the research context, ulotaront's pharmacology is best in class for clean dopaminergic modulation — with empirical guidance supporting once-daily, morning administration in the 25–75 mg window.